GlobeNewswire·Nov 9, 2026, 9:30 AM ET

Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients

ONCY

Oncolytics Biotech Inc. announced translational data from a Phase 1b/2 trial evaluating pelareorep in heavily pretreated relapsed/refractory multiple myeloma patients.
The trial compared cohorts receiving bortezomib, dexamethasone, & pembrolizumab with those receiving the same regimen plus pelareorep.
Patients enrolled had a median of four prior lines of therapy, ranging from three to eleven.
Single-cell analysis revealed enhanced antigen-presenting activity in myeloid cells, including increased CD80 expression & reduced FCGR2B expression.
Multiple myeloma cells showed increased apoptotic & p53 signaling alongside reduced MYC pathway activity.
Treatment resulted in notable increases in CD8 effector memory T cells & upregulation of genes linked to T cell activation & cytotoxic function.
Clinical responders displayed greater expansion of CD8 effector memory T cells compared to non-responders.
Responders also exhibited lower levels of CD8 T cell exhaustion & terminal differentiation than non-responders.
Thomas Heineman, Chief Medical Officer, stated the data supports pelareorep's ability to activate TLR3-mediated antiviral signaling & remodel the tumor microenvironment.
Pelareorep is an investigational immunotherapy that has been administered to over 1,200 patients across multiple solid tumor types.
The Company is advancing pelareorep in metastatic gastrointestinal cancers where it holds Fast Track designation from the FDA.
Oncolytics is actively pursuing strategic partnerships to accelerate development & maximize commercial impact.

Company: Oncolytics Biotech, Inc.
Keywords: Nasdaq:ONCY, Oncolytics Biotech, Inc., oncology, oncolytic virus, oncology immunology, immunology